Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Journal of International Commerce Economics and Policy ; 13(01):30, 2022.
Article in English | Web of Science | ID: covidwho-1896069

ABSTRACT

This paper presents how volatility propagates through the cryptocurrency market. Our paper provides evidence for volatility connectedness on cryptocurrencies. The different econometric techniques, including the stochastic volatility (SVOL) model and time-varying parameter VAR models using a quasi-Bayesian local likelihood (QBLL), are applied to measure the volatility of the cryptocurrency market. Using high-frequency, intra-day data of the largest cryptocurrencies over 2018-2021, we detect the great volatility of the cryptocurrency market are the beginning of 2019, the beginning of 2020, and throughout the year of 2021. The total connectedness values suggest that the cryptocurrency market becomes volatile as the new strains of the COVID-19 appear at the end of 2021. However, by using directional connectedness, we reveal that there are negative and positive spillovers from a specific cryptocurrency to other cryptocurrencies. The great fluctuations in the period before the COVID-19 health crisis stem from the positive resonance (symmetric) between the volatility of each cryptocurrency, while this health crisis leads to substantially positive and negative spillovers (asymmetric) of cryptocurrencies, and this makes market volatility weaker than it actually is.

2.
2nd International Conference on Electronics, Communications and Information Technology, CECIT 2021 ; : 292-297, 2021.
Article in English | Scopus | ID: covidwho-1831727

ABSTRACT

COVID-19 is breaking out and spreading globally, posing a severe threat to public health and economies worldwide due to its highly transmissible and pathogenic nature. Early, accurate and rapid diagnosis of COVID-19 can effectively stop the spread of the COVID-19 virus. Automatic diagnostic models based on deep learning can detect COVID-19 quickly and accurately. This paper uses a three-dimensional Convolutional Neural Network (3D CNN) to build a COVID-19 diagnostic prediction model for COVID-19 detection. All 192 sets of chest Computed Tomography(CT) data collected are used for this study, including 96 sets of confirmed COVID-19 patients and 96 sets of CT scans of normal human lungs. 5-fold cross-validation is used to train and validate the model. 154 data sets are used to train the model, and 38 sets are used for testing. All experimental data are segmented using a pre-trained SP-V-Net to obtain 3D lung masks fed into 3D CNN for training and validation of the prediction model. In addition, to verify the accuracy of the model predictions and provide interpretability for medical diagnosis, we visualize the experimental results using Class Activation Maps(CAM) to localize the predicted disease regions. The results from several experiments show that the accuracy of our prediction model is 0.911, the Area Under Curve (AUC) 0.976, for no-COVID-19(Precision, 0.902, Recall 0.911, F1-Score 0.900), COVID-19 (Precision, 0.932, Recall 0.911, F1-Score 0.902). The experimental results show that our established diagnostic model can help physicians make a rapid and accurate diagnosis of COVID-19 in response to the spread of COVID-19. © 2021 IEEE.

4.
European Journal of Integrative Medicine ; 48, 2021.
Article in English | EMBASE | ID: covidwho-1587782

ABSTRACT

Introduction: Coronavirus Disease 2019 (COVID-19) is an acute respiratory infectious disease. At present, there is no specific and effective therapy for the treatment and prevention of this disease. Traditional Chinese medicine (TCM) has accumulated thousands of years of experience on the use of Chinese herbal medicine (CHM) to prevent and treat infectious diseases. The aim of this study was to present the evidence on the therapeutic effects and safety of Chinese herbal medicine (CHM) used with or without conventional western therapy for COVID-19. Methods: Clinical studies on the therapeutic effects and safety of CHM for COVID-19 were included. We summarized the general characteristics of included studies, evaluated methodological quality of randomized controlled trials (RCTs) using the Cochrane risk of bias tool, analyzed the use of CHM, used Revman 5.4 software to present the risk ratio (RR) or mean difference (MD) and their 95% confidence interval (CI) to estimate the therapeutic effects and safety of CHM. Results: A total of 58 clinical studies were identified including RCTs (17.24%, 10), non-randomized controlled trials (1.72%, 1), retrospective studies with a control group (18.97%, 11), case-series (20.69%, 12) and case-reports (41.38%, 24). Fig.1 shows the flow diagram for the searching and screening of published articles. No RCTs of high methodological quality were identified. The most frequently tested oral Chinese patent medicine, Chinese herbal medicine injection or prescribed herbal decoction were: Lianhua Qingwen granule/capsule, Xuebijing injection and Maxing Shigan Tang. Table 1 lists the CHM used at least twice. In terms of aggravation rate, pooled analyses showed that there were statistical differences between the intervention group and the comparator group (RR 0.42, 95% CI 0.21 to 0.82, six RCTs;RR 0.38, 95% CI 0.23 to 0.64, five retrospective studies with a control group), that is, CHM plus conventional western therapy appeared better than conventional western therapy alone in reducing aggravation rate. In addition, compared with conventional western therapy, CHM plus conventional western therapy had potential advantages in increasing the recovery rate and shortening the duration of fever, cough and fatigue, improving the negative conversion rate of nucleic acid test, and increasing the improvement rate of chest CT manifestations and shortening the time from receiving the treatment to the beginning of chest CT manifestations improvement. For adverse events, pooled data showed that there were no statistical differences between the CHM and the control groups. Conclusion: Current low certainty evidence suggests that there may be a tendency that CHM plus conventional western therapy is superior to conventional western therapy alone. The use of CHM did not increase the risk of adverse events. Keywords: traditional Chinese medicine, Chinese herbal medicine, novel coronavirus pneumonia, coronavirus disease 2019, COVID-19, SARS-CoV-2, review, clinical study

5.
Global Advances in Health and Medicine ; 10:24-25, 2021.
Article in English | EMBASE | ID: covidwho-1234517

ABSTRACT

Objective: To present the evidence of the effectiveness and safety of Chinese herbal medicine (CHM) used with or without conventional western therapy on COVID-19. Methods: Clinical studies on effectiveness and safety of CHM for COVID-19 were included. We summarized general characteristics of included studies, evaluated methodological quality of randomized controlled trials (RCTs), analyzed the use of CHM, estimated the effectiveness and safety of CHM. Results: A total of 58 clinical studies were identified including RCTs (17.24%, 10), non-randomized controlled trials (1.72%, 1), retrospective studies with a control group (18.97%, 11), case-series (20.69%, 12) and case-reports (41.38%, 24). No high methodological quality RCTs were identified. The most frequently tested Chinese patent medicine, Chinese herbal medicine injection or prescribed herbal decoction were: Lianhua Qingwen granule/capsule, Xuebijing injection and Maxing Shigan Tang. In terms of aggravation rate, pooled analyses showed that there had statistical differences between the intervention group and the comparator group (RR 0.42, 95% CI 0.21 to 0.82, 6 RCTs;RR 0.37, 95% CI 0.22 to 0.64, 4 retrospective studies with control group), that is, CHM plus conventional western therapy appeared better than conventional western therapy in reducing aggravation rate. In addition, compared with conventional western therapy, CHM plus conventional western therapy had potential advantages in increasing the resolution rate and shortening the duration of fever, cough and fatigue, improving the negative conversion rate of nucleic acid test, and increasing the number of patients with inflammatory disappearance or shortening the time from receiving treatment to beginning of inflammation disappearance. For adverse events, pooled data showed that there was no statistical difference between the CHM and the control groups. Conclusion: Current low certainty evidence suggests that there may be a tendency that CHM plus conventional western therapy is superior to conventional western therapy alone. The use of CHM did not increase the risk of adverse events.

6.
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences ; 52(4):780-784, 2020.
Article in Chinese | MEDLINE | ID: covidwho-724913

ABSTRACT

The novel coronavirus is a newly discovered pathogen in late December 2019, and its source is currently unknown, which can lead to asymptomatic infection, new coronavirus pneumonia or serious complications, such as acute respiratory failure. Corona virus disease 2019 (COVID-19) is a new type of respiratory disease that is currently spreading all over the world and caused by this coronavirus. Its common symptoms are highly similar to those of other viruses, such as fever, cough and dyspnea. There is currently no vaccine or treatment for COVID-19. Everyone is susceptible to infection with this disease, and owing to the long-term use of immunosuppressants, the immunity of kidney transplant recipients is suppressed, and it is more likely to be infected with the disease. At present, its impact on kidney transplant recipients is unclear. This article reports the clinical features and therapeutic course of novel coronavirus infection in a patient after renal transplantation. A 37-year-old female patient who received a kidney transplant 6 months before was diagnosed with novel coronavirus pneumonia. The patient's symptoms (such as fever, chills, dry cough, muscle aches), laboratory tests (such as decreased white blood cell count, elevated liver enzymes and D-dimer, positive viral nucleic acid test), and chest CT (multiple left lower lung plaque ground glass shadow) were similar to those of non-transplanted novel coronavirus pneumonia patients. In terms of treatment, because the immunity of kidney transplant recipients has been suppressed for a long time, it is a very common strategy to suspend the use of immunosuppressive agents. Therefore, the patient immediately discontinued the immunosuppressive agent after admission, so that she could restore immunity against infection in a short time. At the same time, the use of glucocorticoids was also very important. Its immunosuppressive and anti-inflammatory effects played a large role in the treatment process.In addition, prophylactic antibiotics was needed, and nephrotoxic drugs should be used with caution. Finally, following discounting the use of immunosuppressant and a low-dose glucocorticoid-based treatment regimen, COVID-19 in this renal transplant recipient was successfully cured. The cure of this case was of great significance, and this adjuvant nonspecific antiviral therapy could provide a template for the treatment of other such patients.

SELECTION OF CITATIONS
SEARCH DETAIL